Definitive Healthcare Corp. (NASDAQ:DH) Receives Average Rating of “Reduce” from Brokerages

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have earned an average rating of “Reduce” from the nine research firms that are currently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $2.4714.

DH has been the topic of several research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Wednesday, June 3rd. Wall Street Zen raised shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Sunday. Zacks Research raised shares of Definitive Healthcare from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. Barclays decreased their target price on shares of Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating on the stock in a research report on Monday, March 30th. Finally, Robert W. Baird set a $1.10 price target on shares of Definitive Healthcare in a research note on Friday, May 8th.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of DH. Raymond James Financial Inc. bought a new stake in shares of Definitive Healthcare in the 2nd quarter valued at about $32,000. State of Alaska Department of Revenue grew its position in Definitive Healthcare by 109.3% during the 4th quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock worth $32,000 after acquiring an additional 5,970 shares during the last quarter. Schonfeld Strategic Advisors LLC bought a new position in Definitive Healthcare during the 4th quarter worth approximately $35,000. Bayesian Capital Management LP purchased a new position in Definitive Healthcare in the 2nd quarter worth approximately $55,000. Finally, Prelude Capital Management LLC purchased a new position in Definitive Healthcare in the 3rd quarter worth approximately $64,000. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Stock Performance

Shares of NASDAQ DH opened at $0.68 on Monday. The stock has a market cap of $72.07 million, a price-to-earnings ratio of -0.42, a P/E/G ratio of 11.02 and a beta of 1.33. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.81. Definitive Healthcare has a 1-year low of $0.62 and a 1-year high of $4.70. The stock’s 50-day moving average is $0.81 and its 200 day moving average is $1.24.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Thursday, May 7th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $55.93 million during the quarter, compared to the consensus estimate of $55.02 million. Definitive Healthcare had a positive return on equity of 4.04% and a negative net margin of 76.04%.Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. On average, sell-side analysts anticipate that Definitive Healthcare will post 0.04 EPS for the current fiscal year.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.